Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline

American Journal of Tropical Medicine and Hygiene

Volumn 90, Issue 4, 2014, Pages 617-620

  Brito, Graça ^a   Dourado, Mayra ^a   Polari, Ludmila ^a   Celestino, Daniela ^a   Carvalho, Lucas P ^a   Queiroz, Adriano ^a   Carvalho, Edgar M ^b   Machado, Paulo R L ^a   Passos, Sara ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b HUPES   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEGLUMINE ANTIMONATE; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TREATMENT FAILURE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFLAMMATION; LOSS OF APPETITE; MALE; NAUSEA; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; TREATMENT OUTCOME; VOMITING;

ADULT; ANTIMONY; CHEMOKINE CCL3; CHEMOKINE CXCL10; CHEMOKINE CXCL9; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; LEISHMANIASIS, CUTANEOUS; MALE; PENTOXIFYLLINE; PILOT PROJECTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84898762254     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.12-0729     Document Type: Article

References (20)

1. WHO, 1998. Leishmaniasis. Tropical Diseases Research. Geneva: WHO.
2. Newlove T, Guimaraes LH, Morgan DJ, Alcantara L, Glesby MJ, Carvalho EM, Machado PR, 2011. Antihelminthic therapy and antimony in cutaneous leishmaniasis: a randomized, double-blind, placebo-controlled trial in patients co-infected with helminths and Leishmania braziliensis. Am J Trop Med Hyg 84: 551-555.
3. Machado PR, Ampuero J, Guimaraes LH, Villasboas L, Rocha AT, Schriefer A, Sousa RS, Talhari A, Penna G, Carvalho EM, 2010. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis 4: e912.
4. D'Oliveira A Jr, Machado P, Bacellar O, Cheng LH, Almeida RP, Carvalho EM, 2002. Evaluation of IFN-gamma and TNFalpha as immunological markers of clinical outcome in cutaneous leishmaniasis. Rev Soc Bras Med Trop 35: 7-10.
5. Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ, 2005. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett 101: 226-230. (Pubitemid 41368083)
6. Dinarello CA, 1997. Role of pro-and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 11: 91-103. (Pubitemid 28045963)
7. Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, Palomo-Cetina A, 1994. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect Immun 62: 837-842. (Pubitemid 24065562)
8. Santos JB, de Jesus AR, Machado PR, Magalhaes A, Salgado K, Carvalho EM, Almeida RP, 2004. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis 190: 1793-1796. (Pubitemid 39487824)
9. Ward A, Clissold SP, 1987. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50-97. (Pubitemid 17092322)
10. Gutierrez-Reyes G, Lopez-Ortal P, Sixtos S, Cruz S, Ramirez-Iglesias MT, Gutierrez-Ruiz MC, Sanchez-Avila F, Roldan E, Vargas-Vorackova F, Kershenobich D, 2006. Effect of pentoxifylline on levels of pro-inflammatory cytokines during chronic hepatitis C. Scand J Immunol 63: 461-467. (Pubitemid 43978861)
11. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA, 1991. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110: 192-196.
12. Sadeghian G, Nilforoushzadeh MA, 2006. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol 45: 819-821. (Pubitemid 43984390)
13. Machado PR, Lessa H, Lessa M, Guimaraes LH, Bang H, Ho JL, Carvalho EM, 2007. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis 44: 788-793. (Pubitemid 46365302)
14. Lessa HA, Machado P, Lima F, Cruz AA, Bacellar O, Guerreiro J, Carvalho EM, 2001. Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony. Am J Trop Med Hyg 65: 87-89. (Pubitemid 32746963)
15. Reed SG, Badaro R, Masur H, Carvalho EM, Lorenco R, Lisboa A, Teixeira R, Johnson WD Jr, Jones TC, 1986. Selection of a skin test antigen for American visceral leishmaniasis. Am J Trop Med Hyg 35: 79-85. (Pubitemid 16140841)
16. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G, 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 182: 155-162.
17. Kasama T, Muramatsu M, Kobayashi K, Yajima N, Shiozawa F, Hanaoka R, Miwa Y, Negishi M, Ide H, Adachi M, 2002. Interaction of monocytes with vascular endothelial cells synergistically induces interferon gamma-inducible protein 10 expression through activation of specific cell surface molecules and cytokines. Cell Immunol 219: 131-139. (Pubitemid 36262024)
18. Ritter U, Korner H, 2002. Divergent expression of inflammatory dermal chemokines in cutaneous leishmaniasis. Parasite Immunol 24: 295-301. (Pubitemid 34779848)
19. Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, Scherberich J, Schmitz J, Shortman K, Sozzani S, Strobl H, Zembala M, Austyn JM, Lutz MB, 2010. Nomenclature of monocytes and dendritic cells in blood. Blood 116: e74-e80.
20. Zawada AM, Rogacev KS, Rotter B, Winter P, Marell RR, Fliser D, Heine GH, 2011. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 118: e50-e61.